These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 1545130)
1. Borrelia burgdorferi strain 25015: characterization of outer surface protein A and vaccination against infection. Fikrig E; Barthold SW; Persing DH; Sun X; Kantor FS; Flavell RA J Immunol; 1992 Apr; 148(7):2256-60. PubMed ID: 1545130 [TBL] [Abstract][Full Text] [Related]
2. Protective immunization with plasmid DNA containing the outer surface lipoprotein A gene of Borrelia burgdorferi is independent of an eukaryotic promoter. Simon MM; Gern L; Hauser P; Zhong W; Nielsen PJ; Kramer MD; Brenner C; Wallich R Eur J Immunol; 1996 Dec; 26(12):2831-40. PubMed ID: 8977275 [TBL] [Abstract][Full Text] [Related]
3. T helper cell priming of mice to Borrelia burgdorferi OspA leads to induction of protective antibodies following experimental but not tick-borne infection. Zhong W; Gern L; Kramer M; Wallich R; Simon MM Eur J Immunol; 1997 Nov; 27(11):2942-7. PubMed ID: 9394822 [TBL] [Abstract][Full Text] [Related]
4. Plasmid DNA and protein vaccination of mice to the outer surface protein A of Borrelia burgdorferi leads to induction of T helper cells with specificity for a major epitope and augmentation of protective IgG antibodies in vivo. Zhong W; Wiesmüller KH; Kramer MD; Wallich R; Simon MM Eur J Immunol; 1996 Nov; 26(11):2749-57. PubMed ID: 8921965 [TBL] [Abstract][Full Text] [Related]
5. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. Luke CJ; Carner K; Liang X; Barbour AG J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201 [TBL] [Abstract][Full Text] [Related]
6. A new approach to a Lyme disease vaccine. Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174 [TBL] [Abstract][Full Text] [Related]
7. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease. Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody. Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491 [TBL] [Abstract][Full Text] [Related]
9. Long-term protection of mice from Lyme disease by vaccination with OspA. Fikrig E; Barthold SW; Kantor FS; Flavell RA Infect Immun; 1992 Mar; 60(3):773-7. PubMed ID: 1541551 [TBL] [Abstract][Full Text] [Related]
10. Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice. Bockenstedt LK; Fikrig E; Barthold SW; Flavell RA; Kantor FS J Immunol; 1996 Dec; 157(12):5496-502. PubMed ID: 8955199 [TBL] [Abstract][Full Text] [Related]
11. Inability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice. Bockenstedt LK; Fikrig E; Barthold SW; Kantor FS; Flavell RA J Immunol; 1993 Jul; 151(2):900-6. PubMed ID: 8335917 [TBL] [Abstract][Full Text] [Related]
13. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination. Molloy PJ; Berardi VP; Persing DH; Sigal LH Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394 [TBL] [Abstract][Full Text] [Related]
14. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. Koide S; Yang X; Huang X; Dunn JJ; Luft BJ J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380 [TBL] [Abstract][Full Text] [Related]
15. Vaccination against lyme disease with recombinant Borrelia burgdorferi outer-surface protein A (rOspA) in horses. Chang Y; Novosol V; McDonough SP; Chang CF; Jacobson RH; Divers T; Quimby FW; Shin S; Lein DH Vaccine; 1999 Oct; 18(5-6):540-8. PubMed ID: 10519945 [TBL] [Abstract][Full Text] [Related]
16. An ospA frame shift, identified from DNA in Lyme arthritis synovial fluid, results in an outer surface protein A that does not bind protective antibodies. Fikrig E; Liu B; Fu LL; Das S; Smallwood JI; Flavell RA; Persing DH; Schoen RT; Barthold SW; Malawista SE J Immunol; 1995 Dec; 155(12):5700-4. PubMed ID: 7499856 [TBL] [Abstract][Full Text] [Related]
17. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Fikrig E; Barthold SW; Kantor FS; Flavell RA Science; 1990 Oct; 250(4980):553-6. PubMed ID: 2237407 [TBL] [Abstract][Full Text] [Related]
18. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi. Luke CJ; Huebner RC; Kasmiersky V; Barbour AG Vaccine; 1997; 15(6-7):739-46. PubMed ID: 9178476 [TBL] [Abstract][Full Text] [Related]
19. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA. Ding W; Huang X; Yang X; Dunn JJ; Luft BJ; Koide S; Lawson CL J Mol Biol; 2000 Oct; 302(5):1153-64. PubMed ID: 11183781 [TBL] [Abstract][Full Text] [Related]
20. Artificial-infection protocols allow immunodetection of novel Borrelia burgdorferi antigens suitable as vaccine candidates against Lyme disease. Wallich R; Jahraus O; Stehle T; Tran TT; Brenner C; Hofmann H; Gern L; Simon MM Eur J Immunol; 2003 Mar; 33(3):708-19. PubMed ID: 12616491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]